Clinical trials: Cell Function
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Diabetes Mellitus, Type 2
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants…
- Trial name
- NCT02009488
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
New-onset Type 1 Diabetes
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
The objective of this clinical trial was to assess whether ladarixin treatment is effective to improve glycemic control in newly diagnosed Type 1 Diabetes (T1D) adult patients with preserved β-cell function.
- Trial name
- NCT04899271
- Testing
- Ladarixin
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Dompé Farmaceutici S.p.A
Treatment of Type I Diabetes Mellitus.
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients.
- Trial name
- NCT01947569
- Testing
- Biological
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- DiaVacs, Inc.
Type 2 Diabetes, High Blood Pressure
Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure…
- Conditions
- Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
- Trial name
- RESILIENCE (NCT03686657)
- Testing
- Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
- Where
- United States
- Sponsor
- ARKAY Therapeutics
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
- Trial name
- NCT02386982
- Testing
- HMS5552
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hua Medicine Limited
Type 1 Diabetes Mellitus
Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas.
- Trial name
- NCT03272269
- Testing
- IMCY-0098
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 41 people
- Sponsor
- Imcyse SA
Autophagy, Healthy Aging
Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy
The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.
- Trial name
- NCT07675200
- Testing
- Spermidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Nutraland USA, Inc.
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Burn Pit Exposure, Airborne Hazard Exposure
Project PHOENIX: Molecular Signatures of Burn Pit Exposure
Project PHOENIX is an observational clinical research study designed to characterize molecular, genomic, cellular, and functional features in blood specimens from former U.S.
- Conditions
- Burn Pit Exposure, Airborne Hazard Exposure, Veteran Health, Deployment-Related Toxic Exposure
- Trial name
- PHOENIX (NCT07562243)
- Testing
- Prior Burn Pit Exposure, No Known Burn Pit Exposure
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Creative Medical Technology Holdings Inc
Type 2 Diabetes Mellitus
Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin
HIP2B is being developed for the treatment of type 1 and type 2 diabetes mellitus. The purpose of this study is to investigate the safety and tolerability of repeat doses of HIP2B in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01933256
- Testing
- HIP2B
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- CureDM
Breast Cancer, Triple Negative Breast Cancer
Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)
Pear Bio has developed an organ-on-a-chip device together with a computer vision pipeline through which the response of an individual patient's tumor to different systemic therapy regimens can be tested simultaneously ex vivo.
- Trial name
- PEAR-MET (NCT06182306)
- Testing
- Biopsy
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Ourotech, Inc.
Irritable Bowel Syndrome
A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome
Emerging evidence indicates the presence of low-grade mucosal inflammation and its pathogenetic role in IBS. The aim of this pilot study is to provide that mesalazine treatment of IBS patients reduces low grade colonic…
- Trial name
- NCT00774007
- Testing
- mesalazine
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- SOFAR S.p.A.
Type1diabetes
Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function
To evaluate the safety and efficacy of Stem cells from human exfoliated teeth transplantation in patients with Islet function decreased significantly to provides scientific basis for further clinical studies to verify the safety…
- Trial name
- NCT03912480
- Testing
- Stem cells from human exfoliated teeth
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs)
- Trial name
- RAMSETE/CDE16 (NCT00688623)
- Testing
- Everolimus
- Where
- 40 sites in France, Germany and 6 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).
- Trial name
- DREAMM12 (NCT04398745)
- Testing
- Belantamab mafodotin
- Where
- 4 sites in Greece, South Korea
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetic Patients, Insufficient Metabolic Control
Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin
The aim of the study is to show that treatment with Glargine will lead to an improvement in beta cell function especially within times of maximal beta cell stress occurring after a meal.
- Conditions
- Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment
- Trial name
- NCT00941148
- Testing
- Insulin Glargin, NPH insulin, Insulin detemir
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- ikfe-CRO GmbH
Diabetes, Type I
A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
Purpose: The purpose of the trial is to assess the safety profile of the study treatment and to evaluate its efficacy in terms of improvement in key diabetes management parameters, including insulin requirements and β-cell…
- Trial name
- IMMUNOSTEM (NCT06938334)
- Testing
- Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Altheia Science
Chronic Lymphocytic Leukemia
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Since in most cases CLL remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival.
- Trial name
- PROVIDENCE (NCT06125795)
- Where
- 25 sites in Spain
- Volunteers
- 146 people
- Sponsor
- AbbVie